Laut Robert-Koch-Institut waren die Influenza-Vakzinen für das Jahr 2018/2019 nur zu etwa 20% effektiv. Neue antiinfektive Wirkstoffe und Therapiekonzepte soll nun das Projekt iCAIR ® (Fraunhofer International Consortium for Anti-Infective Research) entwickeln, insbesondere für das InfluenzaVirus, das Parainfluenza-Virus, die Bakterien Pseudomonas aeruginosa und Neisseria meningitidis sowie für den Pilz Aspergillus fumigatus. Der Anspruch des Konsortiums: Neue Wirkstoffe sollen schnellstmöglich vom Labor in die präklinische Phase überführt werden. Das Fraunhofer-Institut für Toxikologie und Experimentelle Medizin ITEM verfügt über spezielle Testsysteme, um WirkstoffkandiKompass Pneumol 2020;8:53–56 DOI: 10.1159/000505307
{"title":"Kaleidoskop","authors":"Ralf Mohr","doi":"10.1159/000505307","DOIUrl":"https://doi.org/10.1159/000505307","url":null,"abstract":"Laut Robert-Koch-Institut waren die Influenza-Vakzinen für das Jahr 2018/2019 nur zu etwa 20% effektiv. Neue antiinfektive Wirkstoffe und Therapiekonzepte soll nun das Projekt iCAIR ® (Fraunhofer International Consortium for Anti-Infective Research) entwickeln, insbesondere für das InfluenzaVirus, das Parainfluenza-Virus, die Bakterien Pseudomonas aeruginosa und Neisseria meningitidis sowie für den Pilz Aspergillus fumigatus. Der Anspruch des Konsortiums: Neue Wirkstoffe sollen schnellstmöglich vom Labor in die präklinische Phase überführt werden. Das Fraunhofer-Institut für Toxikologie und Experimentelle Medizin ITEM verfügt über spezielle Testsysteme, um WirkstoffkandiKompass Pneumol 2020;8:53–56 DOI: 10.1159/000505307","PeriodicalId":306175,"journal":{"name":"Karger Kompass Pneumologie","volume":"15 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2020-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"116861590","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Background: Medical history, thoracentesis, and imaging features are usually the first steps in the investigation of a possible malignant pleural effusion (MPE). Unfortunately, the diagnostic yield of thoracentesis in this situation is suboptimal even if the procedure is repeated, especially in the context of malignant pleural mesothelioma (MPM). The next step for confirming the diagnosis, if clinically appropriate, is thoracoscopy, but not all patients are fit to undergo this procedure, so the diagnosis is then based on the medical history and imaging features only. Objectives: Our objective was to evaluate the diagnostic value of the medical history and imaging features in MPM. Methods: We reviewed the imaging and medical charts of 92 patients with a final diagnosis of MPE included in our prospective medical thoracoscopy database. The clinical characteristics and imaging features of patients with primary MPE were compared with those of patients with secondary MPE. Results: Male sex (82 vs. 59%, p = 0.02), asbestos exposure (58 vs. 10%, p < 0.001), and mediastinal (68 vs. 33%, p = 0.04), diaphragmatic (75 vs. 31%, p = 0.001) and circumferential pleural thickening (55 vs. 19% p = 0.001) were significantly more frequent in MPM patients. In a multivariate linear regression model, only asbestos exposure (OR 11.2; 95% CI 3.4-36.9) and circumferential pleural thickening (OR 4.7; 95% CI 1.6-13.9) were significantly associated with a diagnosis of MPM. Conclusion: In situations where it is impossible to obtain adequate pleural samples to differentiate MPM from a secondary pleural malignancy, the combination of circumferential pleural thickening and a history of asbestos exposure may be sufficient to make a clinical diagnosis.
背景:病史、胸腔穿刺和影像学特征通常是诊断恶性胸腔积液(MPE)的第一步。不幸的是，在这种情况下，胸穿刺的诊断率是次优的，即使重复手术，特别是在恶性胸膜间皮瘤(MPM)的情况下。确认诊断的下一步，如果临床合适，是胸腔镜检查，但并不是所有的患者都适合进行胸腔镜检查，因此诊断仅基于病史和影像学特征。目的:我们的目的是评价病史和影像学特征对MPM的诊断价值。方法:我们回顾了我们前瞻性胸腔镜数据库中92例最终诊断为MPE的患者的影像学和医学图表。比较原发性MPE与继发性MPE的临床及影像学特征。结果:男性(82比59%，p = 0.02)、石棉暴露(58比10%，p < 0.001)、纵隔(68比33%，p = 0.04)、膈膜(75比31%，p = 0.001)和围膜增厚(55比19% p = 0.001)在MPM患者中更为常见。在多元线性回归模型中，只有石棉暴露(OR 11.2;95% CI 3.4-36.9)和胸膜周增厚(OR 4.7;95% CI 1.6-13.9)与MPM的诊断显著相关。结论:在无法获得足够的胸膜样本来区分MPM和继发性胸膜恶性肿瘤的情况下，胸膜周增厚和石棉暴露史的结合可能足以做出临床诊断。
{"title":"Malignes Mesotheliom: Die diagnostische Aussagekraft einer Computertomographie kritisch hinterfragen","authors":"S. Keymel","doi":"10.1159/000504462","DOIUrl":"https://doi.org/10.1159/000504462","url":null,"abstract":"Background: Medical history, thoracentesis, and imaging features are usually the first steps in the investigation of a possible malignant pleural effusion (MPE). Unfortunately, the diagnostic yield of thoracentesis in this situation is suboptimal even if the procedure is repeated, especially in the context of malignant pleural mesothelioma (MPM). The next step for confirming the diagnosis, if clinically appropriate, is thoracoscopy, but not all patients are fit to undergo this procedure, so the diagnosis is then based on the medical history and imaging features only. Objectives: Our objective was to evaluate the diagnostic value of the medical history and imaging features in MPM. Methods: We reviewed the imaging and medical charts of 92 patients with a final diagnosis of MPE included in our prospective medical thoracoscopy database. The clinical characteristics and imaging features of patients with primary MPE were compared with those of patients with secondary MPE. Results: Male sex (82 vs. 59%, p = 0.02), asbestos exposure (58 vs. 10%, p < 0.001), and mediastinal (68 vs. 33%, p = 0.04), diaphragmatic (75 vs. 31%, p = 0.001) and circumferential pleural thickening (55 vs. 19% p = 0.001) were significantly more frequent in MPM patients. In a multivariate linear regression model, only asbestos exposure (OR 11.2; 95% CI 3.4-36.9) and circumferential pleural thickening (OR 4.7; 95% CI 1.6-13.9) were significantly associated with a diagnosis of MPM. Conclusion: In situations where it is impossible to obtain adequate pleural samples to differentiate MPM from a secondary pleural malignancy, the combination of circumferential pleural thickening and a history of asbestos exposure may be sufficient to make a clinical diagnosis.","PeriodicalId":306175,"journal":{"name":"Karger Kompass Pneumologie","volume":"102 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2020-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"122417588","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Patienten mit interstitiellen Lungenerkran kungen (ILDs) haben ein hohes Risiko, eine Lungenfibrose zu entwickeln, die ihre Le bensqualität stark beeinträchtigt und mit einer schlechten Prognose einhergeht [1–4]. Eine zugelassene Behandlungsoption steht für die idiopathische Lungenfibrose (IPF) zur Verfügung, während andere Lungenfi brosen bislang nicht zielgerichtet therapiert werden können [1, 5, 6]. Die positiven klini schen Erfahrungen bei IPF waren zusammen mit präklinischen Studien die Rationale, um Nintedanib* bei weiteren ILDs zu unter suchen, für die Nintedanib* gegenwärtig nicht zugelassen ist. In der PhaseIIIStudie INBUILD® konnte Nintedanib* erstmals bei vielen unterschiedlichen progredient verlau fenden, fibrosierenden ILDs den Krankheits
{"title":"PharmaNews","authors":"","doi":"10.1159/000506172","DOIUrl":"https://doi.org/10.1159/000506172","url":null,"abstract":"Patienten mit interstitiellen Lungenerkran kungen (ILDs) haben ein hohes Risiko, eine Lungenfibrose zu entwickeln, die ihre Le bensqualität stark beeinträchtigt und mit einer schlechten Prognose einhergeht [1–4]. Eine zugelassene Behandlungsoption steht für die idiopathische Lungenfibrose (IPF) zur Verfügung, während andere Lungenfi brosen bislang nicht zielgerichtet therapiert werden können [1, 5, 6]. Die positiven klini schen Erfahrungen bei IPF waren zusammen mit präklinischen Studien die Rationale, um Nintedanib* bei weiteren ILDs zu unter suchen, für die Nintedanib* gegenwärtig nicht zugelassen ist. In der PhaseIIIStudie INBUILD® konnte Nintedanib* erstmals bei vielen unterschiedlichen progredient verlau fenden, fibrosierenden ILDs den Krankheits","PeriodicalId":306175,"journal":{"name":"Karger Kompass Pneumologie","volume":"32 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2020-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"126754052","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Thomas Crowhurst, Joshua Lightfoot, Aeneas Yeo, Benjamin Reddi, Phan Nguyen, Helen Whitford, Chien-Li Holmes-Liew
Hintergrund: In der Literatur werden nur wenige Fälle von multiplen Bronchusstenosen beschrieben, und keiner von vergleichbarer Schwere wie der unsere. Dieser Fall ist von Relevanz aufgrund seiner Seltenheit, der zu gewinnenden pathophysiologischen Erkenntnisse, der erfolgreich angewandten interventionell-pneumologischen Behandlungsstrategien, und seiner möglichen Beispielrolle für eine seltene Indikation für eine Hochrisiko-Lungentransplantation. Vorstellung des Falls: Bei einem 47-jährigen Mann traten multiple rezidivierende netzartige Bronchusstenosen auf, 5 Wochen nachdem er eine Episode schwerer Tracheobronchitis durchgemacht hatte, die vermutlich durch eine chemische Inhalationsverletzung verursacht worden war und zunächst zum vollständigen bilateralen Lungenkollaps geführt und eine veno-venöse extrakorporale Membranoxygenierung erforderlich gemacht hatte. Die Stenosen verschlossen die Bronchien an vielen Stellen vollständig und verursachten schwere Typ-II-Ateminsuffizienz, sodass maschinelle Beatmung und eine bronchoskopische Punktion und Dilatation sowie letztlich eine bilaterale Lungentransplantation vorgenommen wurden. Schlussfolgerung: Dieser sehr seltene Fall unterstreicht die Folgemorbidität, die eine verheerende Tracheobronchitis nach sich ziehen kann, wenngleich sie heute im Zeitalter der extrakorporalen Membranoxygenierung kurzfristig überlebt werden kann.
{"title":"Fallbericht zu schweren multiplen Bronchusstenosen bei einem Patienten, der ‹das Unüberlebbare überlebte›","authors":"Thomas Crowhurst, Joshua Lightfoot, Aeneas Yeo, Benjamin Reddi, Phan Nguyen, Helen Whitford, Chien-Li Holmes-Liew","doi":"10.1159/000505086","DOIUrl":"https://doi.org/10.1159/000505086","url":null,"abstract":"Hintergrund: In der Literatur werden nur wenige Fälle von multiplen Bronchusstenosen beschrieben, und keiner von vergleichbarer Schwere wie der unsere. Dieser Fall ist von Relevanz aufgrund seiner Seltenheit, der zu gewinnenden pathophysiologischen Erkenntnisse, der erfolgreich angewandten interventionell-pneumologischen Behandlungsstrategien, und seiner möglichen Beispielrolle für eine seltene Indikation für eine Hochrisiko-Lungentransplantation. Vorstellung des Falls: Bei einem 47-jährigen Mann traten multiple rezidivierende netzartige Bronchusstenosen auf, 5 Wochen nachdem er eine Episode schwerer Tracheobronchitis durchgemacht hatte, die vermutlich durch eine chemische Inhalationsverletzung verursacht worden war und zunächst zum vollständigen bilateralen Lungenkollaps geführt und eine veno-venöse extrakorporale Membranoxygenierung erforderlich gemacht hatte. Die Stenosen verschlossen die Bronchien an vielen Stellen vollständig und verursachten schwere Typ-II-Ateminsuffizienz, sodass maschinelle Beatmung und eine bronchoskopische Punktion und Dilatation sowie letztlich eine bilaterale Lungentransplantation vorgenommen wurden. Schlussfolgerung: Dieser sehr seltene Fall unterstreicht die Folgemorbidität, die eine verheerende Tracheobronchitis nach sich ziehen kann, wenngleich sie heute im Zeitalter der extrakorporalen Membranoxygenierung kurzfristig überlebt werden kann.","PeriodicalId":306175,"journal":{"name":"Karger Kompass Pneumologie","volume":"85 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2020-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"130780161","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Background: UK specific data on the risk of developing hospitalised CAP for patients with underlying comorbidities is lacking. This study compared the likelihood of hospitalised all-cause community acquired pneumonia (CAP) in patients with certain high-risk comorbidities and a comparator group with no known risk factors for pneumococcal disease. Methods: This retrospective cohort study interrogated data in the Hospital Episodes Statistics (HES) dataset between financial years 2012/13 and 2016/17. In total 3,078,623 patients in England (aged ≥18 years) were linked to their hospitalisation records. This included 2,950,910 individuals with defined risk groups and a comparator group of 127,713 people who had undergone tooth extraction with none of the risk group diagnoses. Risk groups studied were chronic respiratory disease (CRD), chronic heart disease (CHD), chronic liver disease (CLD), chronic kidney disease (CKD), diabetes (DM) and post bone marrow transplant (BMT). The patients were tracked forward from year 0 (2012/13) to Year 3 (2016/17) and all diagnoses of hospitalised CAP were recorded. A Logistic regression model compared odds of developing hospitalised CAP for patients in risk groups compared to healthy controls. The model was simultaneously adjusted for age, sex, strategic heath authority (SHA), index of multiple deprivation (IMD), ethnicity, and comorbidity. To account for differing comorbidity profiles between populations the Charlson Comorbidity Index (CCI) was applied. The model estimated odds ratios (OR) with 95% confidence intervals of developing hospitalised CAP for each specified clinical risk group.Results: Patients within all the risk groups studied were more likely to develop hospitalised CAP than patients in the comparator group. The odds ratios varied between underlying conditions ranging from 1.18 (95% CI 1.13, 1.23) for those with DM to 5.48 (95% CI 5.28, 5.70) for those with CRD. Conclusions: Individuals with any of 6 pre-defined underlying comorbidities are at significantly increased risk of developing hospitalised CAP compared to those with no underlying comorbid condition. Since the likelihood varies by risk group it should be possible to target patients with each of these underlying comorbidities with the most appropriate preventative measures, including immunisations.
背景:英国缺乏有潜在合并症的患者发生住院CAP风险的具体数据。本研究比较了具有某些高危合并症的患者和没有已知肺炎球菌疾病危险因素的比较组住院的全因社区获得性肺炎(CAP)的可能性。方法:本回顾性队列研究询问2012/13财政年度至2016/17财政年度医院事件统计(HES)数据集的数据。英格兰共有3078623名患者(年龄≥18岁)与其住院记录相关联。其中包括2,950,910名具有明确风险群体的个体，以及127,713名接受过拔牙但没有任何风险群体诊断的比较组。研究的危险人群为慢性呼吸系统疾病(CRD)、慢性心脏病(CHD)、慢性肝病(CLD)、慢性肾病(CKD)、糖尿病(DM)和骨髓移植后(BMT)。从第0年(2012/13年)到第3年(2016/17年)对患者进行跟踪，记录所有住院CAP的诊断。Logistic回归模型比较了风险组患者与健康对照组相比发生住院CAP的几率。同时根据年龄、性别、战略健康权威(SHA)、多重剥夺指数(IMD)、种族和合并症对模型进行调整。为了解释人群之间不同的共病概况，应用了查理森共病指数(CCI)。该模型以95%的置信区间估计了每个特定临床风险组的住院CAP的优势比(OR)。结果:在所研究的所有危险组中，患者比比较组的患者更有可能发生住院CAP。潜在疾病之间的优势比从DM患者的1.18 (95% CI 1.13, 1.23)到CRD患者的5.48 (95% CI 5.28, 5.70)不等。结论:与没有潜在合并症的患者相比，患有6种预先定义的潜在合并症中的任何一种的患者发生住院CAP的风险显著增加。由于可能性因风险组而异，因此应该有可能针对患有这些潜在合并症的患者采取最适当的预防措施，包括免疫接种。
{"title":"Ambulant erworbene Pneumonie: Komorbiditäten als Risikofaktoren erkennen","authors":"S. Krüger","doi":"10.1159/000504461","DOIUrl":"https://doi.org/10.1159/000504461","url":null,"abstract":"Background: UK specific data on the risk of developing hospitalised CAP for patients with underlying comorbidities is lacking. This study compared the likelihood of hospitalised all-cause community acquired pneumonia (CAP) in patients with certain high-risk comorbidities and a comparator group with no known risk factors for pneumococcal disease. Methods: This retrospective cohort study interrogated data in the Hospital Episodes Statistics (HES) dataset between financial years 2012/13 and 2016/17. In total 3,078,623 patients in England (aged ≥18 years) were linked to their hospitalisation records. This included 2,950,910 individuals with defined risk groups and a comparator group of 127,713 people who had undergone tooth extraction with none of the risk group diagnoses. Risk groups studied were chronic respiratory disease (CRD), chronic heart disease (CHD), chronic liver disease (CLD), chronic kidney disease (CKD), diabetes (DM) and post bone marrow transplant (BMT). The patients were tracked forward from year 0 (2012/13) to Year 3 (2016/17) and all diagnoses of hospitalised CAP were recorded. A Logistic regression model compared odds of developing hospitalised CAP for patients in risk groups compared to healthy controls. The model was simultaneously adjusted for age, sex, strategic heath authority (SHA), index of multiple deprivation (IMD), ethnicity, and comorbidity. To account for differing comorbidity profiles between populations the Charlson Comorbidity Index (CCI) was applied. The model estimated odds ratios (OR) with 95% confidence intervals of developing hospitalised CAP for each specified clinical risk group.Results: Patients within all the risk groups studied were more likely to develop hospitalised CAP than patients in the comparator group. The odds ratios varied between underlying conditions ranging from 1.18 (95% CI 1.13, 1.23) for those with DM to 5.48 (95% CI 5.28, 5.70) for those with CRD. Conclusions: Individuals with any of 6 pre-defined underlying comorbidities are at significantly increased risk of developing hospitalised CAP compared to those with no underlying comorbid condition. Since the likelihood varies by risk group it should be possible to target patients with each of these underlying comorbidities with the most appropriate preventative measures, including immunisations.","PeriodicalId":306175,"journal":{"name":"Karger Kompass Pneumologie","volume":"66 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2020-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"129887087","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
III. Was ist Gesundheitsmanagement?.............................................................................. 6 III.1 Ziele des dienststelleninternen Gesundheitsmanagements.................................................. 6 III.2 Prinzipien und Qualitätskriterien des Gesundheitsmanagements ....................................... 7 III.2.1 Ganzheitlichkeit .............................................................................................................. 7 III.2.2 Partizipation .................................................................................................................... 7 Eine weiterer Aspekt von Partizipation ist Transparenz. Nur wenn über Ziele und Inhalte von Gesundheitsmanagement ausführlich informiert wird und „Gesundheit” in der Dienststelle zum Thema gemacht wird, können Mitarbeiterinnen und Mitarbeiter sowie Führungskräfte zur Mitwirkung und Unterstützung von Gesundheitsmanagement motiviert werden. ..............................?? III. 2.3 Integration und Projektorganisation ........................................................................... 8 III. 2.4 Qualitätskriterien ........................................................................................................... 8 III. 2.5 Gender Mainstreaming.................................................................................................. 9
三。是ist Gesundheitsmanagement ?..............................................................................6 III . 1 Ziele des dienststelleninternen Gesundheitsmanagements ..................................................6质量III . 2 Prinzipien undätskriterien des Gesundheitsmanagements .......................................III . 2。1 Ganzheitlichkeit 7 ..............................................................................................................III . 2 . 2 Partizipation 7 ....................................................................................................................这是透明的。努尔wennüber Ziele und Inhalte von Gesundheitsmanagement ausführlich informiert wird und„Gesundheit”在der Dienststelle zum主题gemacht wird, können Mitarbeiterinnen und Mitarbeiter sowie Führungskräfte zur 533 und Unterstützung von Gesundheitsmanagement motiviert werden . ..............................??三。2.3 Integration and Projektorganisation ...........................................................................8第三。2.4质量ätskriterien ...........................................................................................................8第三。2 .将性别观点纳入主流5 ..................................................................................................9
{"title":"Inhalt","authors":"I. Einleitung","doi":"10.1159/000506169","DOIUrl":"https://doi.org/10.1159/000506169","url":null,"abstract":"III. Was ist Gesundheitsmanagement?.............................................................................. 6 III.1 Ziele des dienststelleninternen Gesundheitsmanagements.................................................. 6 III.2 Prinzipien und Qualitätskriterien des Gesundheitsmanagements ....................................... 7 III.2.1 Ganzheitlichkeit .............................................................................................................. 7 III.2.2 Partizipation .................................................................................................................... 7 Eine weiterer Aspekt von Partizipation ist Transparenz. Nur wenn über Ziele und Inhalte von Gesundheitsmanagement ausführlich informiert wird und „Gesundheit” in der Dienststelle zum Thema gemacht wird, können Mitarbeiterinnen und Mitarbeiter sowie Führungskräfte zur Mitwirkung und Unterstützung von Gesundheitsmanagement motiviert werden. ..............................?? III. 2.3 Integration und Projektorganisation ........................................................................... 8 III. 2.4 Qualitätskriterien ........................................................................................................... 8 III. 2.5 Gender Mainstreaming.................................................................................................. 9","PeriodicalId":306175,"journal":{"name":"Karger Kompass Pneumologie","volume":"29 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2020-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"133158183","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Background: We present a critical comparison of lobectomy and sub-lobar resection in elderly patients with early stage non-small cell lung cancer using meta-analytical techniques. Methods: A literature search was conducted between the period of December 1997 to March 2019 to identify the comparative studies evaluating 1-, 3-, and 5-year survival rates. The pooled odds ratios (OR) and the 95% confidence intervals (95% CI) were calculated with either the fixed or random effect models, respectively. Results: Six retrospective studies are included in our meta-analysis for a total of 1205 patients. 843 of the individuals were treated with lobectomy, while 362 were treated with sub-lobar resection. We found no significant difference between the lobectomy and the sub-lobar resection in either of the 1-, 3-, or 5-year survival rates. Conclusions: This study suggests that in elderly individuals with stage I NSCLC, a sub-lobar resection is statistically equivalent to the lobectomy in terms of 1-, 3-, and 5-year survival rates. Further large-scale randomized studies are needed to confirm our results.
{"title":"Nicht kleinzelliges Lungenkarzinom bei älteren Patienten: Einfluss von Lobektomie oder sublobärer Resektion auf die Prognose","authors":"K. Hekmat","doi":"10.1159/000504031","DOIUrl":"https://doi.org/10.1159/000504031","url":null,"abstract":"Background: We present a critical comparison of lobectomy and sub-lobar resection in elderly patients with early stage non-small cell lung cancer using meta-analytical techniques. Methods: A literature search was conducted between the period of December 1997 to March 2019 to identify the comparative studies evaluating 1-, 3-, and 5-year survival rates. The pooled odds ratios (OR) and the 95% confidence intervals (95% CI) were calculated with either the fixed or random effect models, respectively. Results: Six retrospective studies are included in our meta-analysis for a total of 1205 patients. 843 of the individuals were treated with lobectomy, while 362 were treated with sub-lobar resection. We found no significant difference between the lobectomy and the sub-lobar resection in either of the 1-, 3-, or 5-year survival rates. Conclusions: This study suggests that in elderly individuals with stage I NSCLC, a sub-lobar resection is statistically equivalent to the lobectomy in terms of 1-, 3-, and 5-year survival rates. Further large-scale randomized studies are needed to confirm our results.","PeriodicalId":306175,"journal":{"name":"Karger Kompass Pneumologie","volume":"7 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"129912265","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：